New pill shows promise for severe eczema in major trial
NCT ID NCT05526222
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new oral medication, jaktinib, for adults with moderate to severe atopic dermatitis (eczema). About 443 participants will receive either jaktinib or a placebo to see if it improves skin symptoms like redness and itching. The goal is to find a safe and effective treatment option for people whose eczema is not well controlled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
139 People's Middle Road
Changsha, Hunan, 410008, China